$GSK··Cautiously optimistic
GSK's Bold Move: A Slightly Bullish Take on the Nuvalent Acquisition
GSK has been making headlines recently with its $10.6 billion acquisition of Nuvalent, a U.S.-based cancer drugmaker. This deal caught my attention because it represents a signifi...